Structural and biochemical characterization of the novel CTXM-151 extended-spectrum β-lactamase and its inhibition by avibactam by Ghiglione, Barbara et al.
Structural and Biochemical Characterization of the Novel CTX-
M-151 Extended-Spectrum b-Lactamase and Its Inhibition by
Avibactam
Barbara Ghiglione,a,b,c María Margarita Rodríguez,a,b,c Florencia Brunetti,a,b,c Krisztina M. Papp-Wallace,d,e,f,g Ayumi Yoshizumi,h
Yoshikazu Ishii,h Robert A. Bonomo,d,e,f,g Gabriel Gutkind,a,b,c Sebastián Klinke,i Pablo Powera,b,c
aUniversidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Microbiología, Inmunología y Biotecnología, Laboratorio de Resistencia Bacteriana,
Buenos Aires, Argentina
bConsejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
cInstituto de Investigaciones en Bacteriología y Virología Molecular (IBaViM), Buenos Aires, Argentina
dResearch Service, Louis Stokes Cleveland Department of Veterans Affairs, Cleveland, Ohio, USA
eDepartment of Medicine, Case Western Reserve University, Cleveland, Ohio, USA
fCenter for Proteomics and Bioinformatics, Case Western Reserve University, Cleveland, Ohio, USA
gDepartment of Biochemistry, Case Western Reserve University, Cleveland, Ohio, USA
hDepartment of Microbiology and Infectious Diseases, Toho University, Tokyo, Japan
iFundación Instituto Leloir, IIBBA-CONICET, and Plataforma Argentina de Biología Estructural y Metabolómica PLABEM, Buenos Aires, Argentina
Sebastián Klinke and Pablo Power contributed equally to this work.
ABSTRACT The diazabicyclooctane (DBO) inhibitor avibactam (AVI) reversibly inacti-
vates most serine b-lactamases, including the CTX-M b-lactamases. Currently, more
than 230 unique CTX-M members distributed in five clusters with less than 5%
amino acid sequence divergence within each group have been described. Recently,
a variant named CTX-M-151 was isolated from a Salmonella enterica subsp. enterica
serovar Choleraesuis strain in Japan. This variant possesses a low degree of amino
acid identity with the other CTX-Ms (63.2% to 69.7% with respect to the mature pro-
teins), and thus it may represent a new subgroup within the family. CTX-M-151
hydrolyzes ceftriaxone better than ceftazidime (kcat/Km values 6,000-fold higher), as
observed with CTX-Ms. CTX-M-151 is well inhibited by mechanism-based inhibitors
like clavulanic acid (inactivation rate [kinact]/inhibition constant [Ki] = 0.15mM21 · s21).
For AVI, the apparent inhibition constant (Ki app), 0.4mM, was comparable to that of
KPC-2; the acylation rate (k2/K) (37,000 M21 · s21) was lower than that for CTX-M-15,
while the deacylation rate (koff) (0.0015 s21) was 2- to 14-fold higher than those of
other class A b-lactamases. The structure of the CTX-M-151/AVI complex (1.32 Å)
reveals that AVI adopts a chair conformation with hydrogen bonds between the AVI
carbamate and Ser70 and Ser237 at the oxyanion hole. Upon acylation, the side
chain of Lys73 points toward Ser130, which is associated with the protonation of
Glu166, supporting the role of Lys73 in the proton relay pathway and Glu166 as the
general base in deacylation. To our knowledge, this is the first chromosomally
encoded CTX-M in Salmonella Choleraesuis that shows similar hydrolytic preference
toward cefotaxime (CTX) and ceftriaxone (CRO) to that toward ceftazidime (CAZ).
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Antimicrobial resistance (AMR) has emerged as one of the leading public health crisesof the 21st century, and with the rise of multidrug-resistant (MDR) bacteria, health
care providers are presented with major clinical challenges. Among these, finding
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pharmacologic alternatives to expand the available arsenal to combat bacterial infections
caused by pathogens producing increasingly specialized b-lactamases is mandatory.
Avibactam (AVI) is a bridged bicyclic ((2S,5R)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3,2,1]
octane-2carboxamide) (DBO) non-b-lactam b-lactamase inhibitor (BLI) (Fig. 1a) that
reversibly inactivates most Ambler class A and C b-lactamases and some class D
enzymes (1). AVI follows two routes toward diacylation; the major route is recyclization
via ring closure (i.e., regenerating the intact AVI). Thus, AVI may acylate other b-lacta-
mase molecules (Fig. 1b) (2–6). This reversibility is the main difference between the inac-
tivation of b-lactamases by AVI and the inactivation mechanisms by other BLIs such as
tazobactam, sulbactam, and clavulanic acid. These latter BLIs inactivate via a nucleophilic
attack by the active site serine on the amide bond of the BLI, acylation of the enzyme,
and subsequent rearrangement steps resulting in imine or enamine intermediates, inhib-
itor fragmentation, and a transient or long-term inhibition of the enzyme (7). Despite
these differences, AVI shares some mechanistic similarities with other inhibitors, namely,
a carbonyl carbon atom, acylation of Ser70, and accommodation of the carbonyl oxygen
in the oxyanion hole for stabilization of the transition state (3).
Several crystallographic structures of serine b-lactamases have been solved in com-
plex with AVI, supporting these mechanistic characteristics (3, 4, 8–10). Among class A
b-lactamases, the strains producing CTX-M enzymes have proved to be successfully
inhibited by the ceftazidime (CAZ)-avibactam combination (11).
The CTX-Ms are the most prevalent group of extended-spectrum b-lactamases (ESBLs)
among pathogens around the world, which represent a global pandemic (12–14). CTX-Ms
are generally more efficient in their ability to hydrolyze cefotaxime (CTX) and ceftriaxone
(CRO) than ceftazidime (CAZ), although the spectrum varies by enzyme (15). This behavior
was shown to be the consequence of a more favorable positioning of CTX in the active
site for catalysis, which associated with disruption of a hydrogen bond between Asn170
and Asp240 (16). At this time, at least 230 unique CTX-M alleles are recognized, including
both plasmid-encoded and chromosomal variants in Kluyvera species (17), which are dis-
tributed in at least five gene clusters with less than 5% amino acid sequence differences
within each group (Beta-Lactamase DataBase [http://bldb.eu/]) (18).
An ESBL assigned as CTX-M-151 was recently isolated from a Salmonella enterica
subsp. enterica serovar Choleraesuis TUM12370 strain in Japan (GenBank accession
number NG_048937.1). In this study, we provide the kinetic characterization of this
b-lactamase, along with structural evidence for the inhibition by AVI, and evaluate its
phylogenetic relationship with the rest of the CTX-M family.
FIG 1 (a) Chemical structure of avibactam (AVI). (b) Kinetic model of the interaction of a serine
b-lactamase with AVI.
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Sequence alignment of CTX-M-151. The deduced amino acid sequence of the
b-lactamase from strain TUM12370, deposited as CTX-M-151 (GenBank accession num-
ber BAP34782.1), contains 304 residues. The predicted Sec-type signal peptide covers
the first 23 residues (likelihood, 0.9961) (19), leaving a mature 281-amino-acid
b-lactamase.
This mature protein possessed the highest identity with members from the CTX-M-
9 subgroup. i.e., 68.9% and 69.3% identity with CTX-M-9 and CTX-M-14, respectively.
Similar identity values were observed with some variants, such as CTX-M-64 and CTX-
M-199, among others (20–22), and slightly lower values were observed with members
of the CTX-M-1 (63.2% with CTX-M-15), CTX-M-2 (65%), CTX-M-8 (67.7%), and CTX-M-
25 (66.9%) groups. Sequence alignment revealed the presence of “patches” of con-
served residues, including those relevant for active site architecture (Fig. 2a). We note
that this variant was originally annotated as a “CTX-M-9-like” enzyme within the Beta-
Lactamase DataBase (BLDB [http://bldb.eu/BLDB.php?prot=A#CTX-M]) (18).
A comparative phylogenetic analysis revealed that CTX-M-151, despite its amino acid
differences compared to the rest of the CTX-M family (Fig. 2b), remains more closely
FIG 2 (a) Multiple alignment of amino acid sequences of CTX-M-151 and representative members from the five clusters of CTX-M b-lactamases, using the
class A standard numbering scheme. Only the conserved motifs of the sequences are shown in green boxes for easier visualization. Locations of a-helices
and b-sheets are indicated on the upper side (taken from the PDB file) and relative solvent accessibility on the bottom (blue, highly accessible; cyan,
poorly accessible; white, hidden or nonaccessible). (b) Comparative phylogenetic tree constructed using all the nonredundant CTX-M b-lactamase
sequences in June 2020, compared to selected enzymes from other class A families. Condensed clusters are shown in different colors for easier
visualization of the lack of phylogenetic relationship of CTX-M-151 with the rest of the CTX-Ms.
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related to the CTX-M family (and also to the FONA and OXY enzymes) than to other class
A b-lactamases like TEM/SHV (;40% identity) or KPC (;50% identity), among others.
We stress that the sequence deposited in GenBank (accession number AB916359.1)
shows that the genes immediately upstream and downstream of the bla gene encode
a transcription elongation factor, GreB, and a putative L-lactate dehydrogenase operon
regulatory protein, respectively. Although these neighboring genes are probable chro-
mosomal genes, they are different from the genetic features commonly found associ-
ated with chromosomal blaCTX-M/KLU genes in Kluyvera species, i.e., an aspartate amino
transferase gene located upstream of the blaCTX-M/KLU gene (replaced by an ISEcp1 or an
ISCR element in plasmid-borne blaCTX-M genes), or either open reading frame 3 (orf3) or
orf477 at the downstream region (17, 23).
These combined features suggest that this variant could either represent a new
subfamily within the CTX-M b-lactamases or a new family of class A enzymes closely
related to the CTX-M family. This differentiation will depend on the finding and analysis
of further alleles in different isolates. Important questions remain as to the origin of
this novel allele and the mechanism by which this b-lactamase evolved.
Antimicrobial susceptibility testing. Among the antibiotics tested, the blaCTX-M-151
gene cloned into a pET vector, upon induction with isopropyl-b-D-thiogalactopyrano-
side (IPTG), conferred resistance to only cephalothin and ceftriaxone (CRO) when
expressed in Escherichia coli BL21, and remained susceptible dose dependent (SDD) to
cefepime (when applying the Clinical and Laboratory Standards Institute [CLSI] break-
points). Susceptibility to ceftazidime (CAZ) agrees with the behavior of other “cefotaxi-
mases,” like the CTX-Ms (Table 1). In the source S. Choleraesuis strain TUM12370, resist-
ance to ampicillin, cephalothin, cefoxitin, and CRO was observed, while the isolate
remained intermediate to CAZ and susceptible to aztreonam, cefepime, and imipenem.
Also, AVI inhibited CTX-M-151 in E. coli clones when combined with CAZ.
Biochemical activity of CTX-M-151 reveals a substrate preference for CRO at
the expense of diminished CAZ and penicillin hydrolytic activity. The principal
steady-state kinetic parameters of CTX-M-151 are shown in Table 2. As expected, over-
all greater hydrolytic activity was observed against cephalosporins compared to the
tested penicillins.
The activity toward CRO was at least 6,000-fold greater than toward for CAZ (kcat/
Km, 0.6 versus 0.0001mM21 · s21 for CRO and CAZ, respectively), which resembles the
behavior of most of the CTX-M ESBLs. Regarding CAZ, the low kcat/Km value was mainly
due to an elevated Km value (in the millimolar range), and a very low kcat value. The
poor “ceftazidimase” activity was consistent with susceptibility to CAZ of the parent
clones even after being induced (see Table 1).
Regarding penicillins, activity of CTX-M-151 was greater for piperacillin than ampi-
cillin and benzylpenicillin (catalytic efficiencies were 0.79, 0.33, and 0.26mM21 · s21,
respectively), due to high Km (234mM for ampicillin) and low kcat (12 s21 for












Ampicillin 0.5 0.25 2 128
Cephalothin 0.5 0.5 .128 .256
Cefoxitin 0.5 0.5 0.5 128
Ceftriaxone #0.125 #0.125 64 8
Ceftazidime 0.5 0.5 0.5 8
Ceftazidime-avibactam #0.125 #0.125 #0.125 ND
Cefepime #0.125 #0.125 8 1
Aztreonam #0.125 #0.125 0.5 2
Imipenem #0.125 #0.125 #0.125 0.125
aValues from A. Yoshizumi and Y. Ishii (personal communication). ND, not determined.
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benzylpenicillin) parameters. The “penicillinase” activity of this variant seemed to be
up to 10-fold less than those of other CTX-M b-lactamases (24, 25).
Surprisingly, CTX-M-151 also demonstrated robust catalytic activity against aztreo-
nam (kcat/Km = 0.79mM21 · s21), in spite of the low MIC values observed both in the
source S. Choleraesuis isolate and the transformant E. coli BL21 151-3 strain (Table 1).
Additionally, we observed very poor activity toward imipenem, mostly due to a very
low kcat value (0.001 s21). Activity was not detected against cefoxitin (data not shown),
for which a high MIC value was observed in the S. Choleraesuis isolate, indicating that
additional resistance mechanisms are likely contributing.
Inhibition of CTX-M-151 by clavulanate and AVI. As expected for a class A b-lac-
tamase, CTX-M-151 was well inhibited by clavulanate, with the following parameters:
inhibition constant (Ki) of 0.176 0.03mM, inactivation rate (kinact) of 0.0266 0.001 s21,
and inhibition efficiency (kinact/Ki) of 0.156 0.03mM21 · s21. These values were compa-
rable to the values observed for other ESBLs like CTX-M-96 (0.67mM, 0.03 s21 and
0.045mM21 · s21, respectively) (25) and PER-2 (0.064mM, 0.031 s21 and 0.48mM21 · s21,
respectively) (26).
The apparent inhibition constant (Ki app) for AVI determined by plotting 1/v0 versus
[AVI] was found to be 0.4mM (Table 3); this value is in the same range as that corre-
sponding to KPC-2 (2) but 50-fold lower than that for PER-2 b-lactamase (27). In con-
trast, the Ki app value obtained for CTX-M-151 was 10-fold greater than the value
reported for wild-type SHV-1 (28). The acylation rate, k2/K, was determined in our
assays to be 37,000 M21 · s21 (Table 3). Comparative analysis with other serine b-lacta-
mases revealed that CTX-M-151 displayed similar acylation constants to those of class
A KPC-2 and SHV-1 (2, 6) and class C CMY-2 (28), with k2/K values in the 104 M21 · s21
order (1.7 104 to 6 104 M21 · s21). These values are between 2 and 7.5-fold lower
than k2/K values for other class A b-lactamases, such as TEM-1 and CTX-M-15 (6, 13),
but;10-fold higher than those for class D OXA-48 (2).
TABLE 2 Steady-state kinetic parameters and standard deviations (SD) for CTX-M-151
Substrate Km (mM) Kcat (s21) Kcat/Km (mM21 · s21) Relative kcat/Km (%)a
Nitrocefin 166 2 1706 5 10.66 1.6
Benzyl-penicillin 476 8 12.26 0.6 0.266 0.06 15.3
Ampicillin 2346 41 786 6 0.336 0.08 19.4
Piperacillinb 146 1 116 1 0.796 0.08 46.5
Cephalothin 2406 28 4096 33 1.706 0.34 100
Ceftriaxone 236 3 13.36 0.8 0.66 0.1 35.3
Ceftazidimeb 1,4006 60 0.14 0.00016 0.000001 0.006
Cefepime 2526 75 2006 40 0.796 0.23 46.5
Aztreonam 1336 24 666 4 0.56 0.1 29.4
Imipenemb 136 1 0.0016 0.0001 0.000086 0.00001 0.005
aRelative to cephalothin.
bThe Km values were determined as Ki in competition experiments against nitrocefin as reporter substrate (see
Materials and Methods for further details).
TABLE 3 Comparative enzyme inhibition kinetic parameters and standard deviations (SD) of
CTX-M-151 and other serine b-lactamases against AVI
b-Lactamase Ki app (mM) k2/K (M21 · s21) Koff (s21)
Reference
or source
CTX-M-151 0.46 0.03 3.7 1046 0.1 104 1.5 10236 0.1 1023 This study
CTX-M-15 1.3 105 6 0.1 105 3 1024 6 1 1024 2
PER-2 206 3 2.2 103 6 0.1 103 4 1024 10
KPC-2 1.26 0.1 1.3 1046 0.1 104 1.4 10246 0.1 1024 2
SHV-1 0.0226 0.002 6 104 6
TEM-1 1.6 1056 0.1 105 8 10246 4 1024 1
OXA-48 1.4 1036 0.1 103 1.2 10256 0.4 1025 2
CMY-2 266 3 4.9 1046 0.5 104 3.7 10246 0.4 1024 28
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Recovery of CTX-M-151 activity after inhibition by AVI was measured next. The
deacylation rate, koff, was found to be 0.0015 s21 (Table 3). Interestingly, the off-rate
(koff) for CTX-M-151 was between 2- and 14-fold greater than those for other class A
b-lactamases, with the carbapenemase KPC-2 being the lowest among these enzymes.
Comparing other enzymes, we observed a 125-fold greater rate than that of the carba-
penem-hydrolyzing class D b-lactamase (CHDL) OXA-48 and a 4-fold greater rate than
that of the class C b-lactamase CMY-2.
Crystallographic structure of apo-CTX-M-151 and its complex with AVI. The
structure of the apo form of CTX-M-151 and its covalent complex with AVI were
obtained at resolutions of 1.28 and 1.32Å, respectively. Data collection and refinement




PDB code 6BN3 6BPF
Data collection
No. of frames 3,600 3,600
Oscillation step (o) 0.1 0.1
Detector distance (mm) 126.96 134.26
Wavelength (Å) 0.9801 0.9801
Exposure per frame (s) 0.025 0.025
Space group C 2 C 2
Unit cell parameters (Å [°]) a = 95.79, b = 41.81, c = 56.45
(a = 90, b = 94.14,g= 90)
a = 95.59, b = 41.94, c = 56.36
(a = 90, b = 94.09,g= 90)
No. of subunits/asymmetric units 1 1
Resolution range (Å)a 47.77–1.28 (1.32–1.28) 47.67–1.32 (1.40–1.32)
Total no. of reflections 370,005 337,693
No. of unique reflections 56,860 (5,258) 52,411 (8,155)
Redundancy 6.5 (5.9) 6.4 (5.7)
Completeness (%) 98.1 (91.4) 99.2 (96.1)
Mean I/s (I) 12.5 (1.4) 14.3 (1.3)
Overall Wilson B factor (Å2) 18 18
Rmerge 0.066 (0.847) 0.065 (0.833)
Rmeas 0.072 (0.929) 0.071 (0.919)
CC (1/2) 0.998 (0.834) 0.999 (0.838)
Refinement
No. of reflections used in
refinement
56,738 52,272
Rfree test set (%) 2,839 (5.0) 2,615 (5.0)
Rwork 0.166 0.188
Rfree 0.214 0.213
No. of nonhydrogen atoms 2,309 2,318
No. of macromolecules 2,021 1,986
No. of ligands 15 17
No. of solvents 273 315
RMSb deviations from ideal
stereochemistry
Bonds (Å) 0.006 0.008
Angles (o) 1.11 1.03
Avg B factor (Å2)





Favored regions 97.4 96.9
Allowed regions 2.3 2.7
Outlier regions 0.3 0.4
aStatistics for the highest-resolution shell are given in parentheses.
bRMS, root mean square.
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statistics are given in Table 4. Both structures contained only one monomer per asym-
metric unit, and the electron density map was well defined along the main chain in
both cases (Fig. 3). The protein chains for apo CTX-M-151 and the CTX-M-151/AVI com-
plex include 267 and 265 residues, respectively. The structures were solvated by 273
(apo form) and 315 (AVI complex) ordered water molecules. The average root mean
square deviation (RMSD) values for alpha carbon (C-a) atoms between the main chains
of CTX-M-151 and its complex with AVI was 0.16 Å.
Inspection of the CTX-M-151/AVI complex revealed that AVI was covalently bound
to the Ser70-Og atom upon cleavage of the C-7–N-6 bond, excluding the possibility of
cleavage of the C-7–N-1 bond, in agreement with other structures with bound AVI (9,
10). This was clearly observed in the active site in the well-defined mFo-DFc omit map
contoured at the 2.5-s level for the AVI moiety (Fig. 4a). The 6-membered AVI ring
adopted a chair conformation with hydrogen bonds via the C-7 carbonyl of the newly
formed carbamate (which occupied the place of the catalytic water in the apo struc-
ture, as observed in Fig. 4b and c) to the backbone nitrogen atoms of Ser70 and
Ser237 in the oxyanion hole, and to the carbonyl oxygen atom of Ser237 (2.65, 2.92,
and 3.07 Å, respectively; Fig. 4a). Additional hydrogen bond interactions were observed
(i) between the C-2 amide oxygen atom of AVI and Asn132-Nd2 (2.72 Å), (ii) between
the amide nitrogen atom with two water molecules, (iii) between AVI-N6 with Ser130-
Og (2.94 Å), (iv) via the AVI sulfate moiety with Thr235-O, Thr235-Og, Ser237-Og, and (v)
between two additional water molecules. Further interactions contributing to the
proper fitting of AVI occurred in the active site, creating second-shell hydrogen bonds,
and included Asn104 and Lys73 (through Asn132), Thr216 (through Thr235), and sev-
eral water molecules. The spatial position of the AVI sulfate moiety, equivalent to that
for the b-lactam carboxylate group, was occupied, oddly, by a HEPES molecule in the
apo CTX-M-151 structure (data not shown).
Upon binding of AVI, the deacylating water was slightly displaced outwards Ser70-
Og in comparison to its position in the apo form (2.88 versus 2.59 Å) so that the side
FIG 3 (Upper) Overall structures of the apo CTX-M-151 (green/orange) and its complex with AVI (purple/
orange). (Lower) Detail of the active site of apo CTX-M-151 (left) and the CTX-M-151/AVI complex (right).
Important residues and the AVI molecule are shown surrounded by the corresponding electron density maps
contoured at the 2.5-s level (gray for the apo form and green for the complex) for better visualization. Also,
the conserved water molecules are shown as turquoise (apo enzyme) or orange (complex) spheres; note that in
the CTX-M-151/AVI complex, only the deacylation water is found.
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chains of Glu166 and Asn170 were shifted to create the proper hydrogen bonding net-
work (Fig. 4b). Also, the positions of several water molecules seem to have been
replaced by the piperidine ring and amide moieties of the AVI molecule, which could
presumably take part in a conserved hydrogen bonding network in apo CTX-M-151
(Fig. 4c). In fact, this could give rise to a more favorable environment for creating
hydrophobic interactions between Tyr105 and the 6-membered AVI ring.
More importantly, we observed a subtle yet evident functional difference between
the apo and complex structures, which was also observed in the CTX-M-15/AVI struc-
ture. In the CTX-M-151/AVI complex, the side chain of Lys73 points toward Ser130 (in
the apo structure, Lys73 is oriented toward Glu166 and Ser70 instead), which was asso-
ciated with the protonation of Glu166, observable due to the high resolution of the
structure (Fig. 5), and relevant in the orientation and activation of the deacylating
FIG 4 (a) Stereo view of the CTX-M-151/AVI complex showing the main hydrogen bond interactions in the active site (black dashed lines).
The 2mFo-DFc map is contoured at the 1.5-s level (blue). Water molecules are shown as spheres with different colors, depending on their
function, with deacylating water (DW) in cyan and other important molecules participating in AVI stabilization in green. The relevant Ser70
residue is highlighted in red. (b) Comparative stabilization of the hydrogen bond network (dashed lines) in apo CTX-M-151 (light blue) and
the AVI complex (light orange) and displacement of the deacylating water (DW) upon AVI binding. CW, catalytic water. (c) Position of
additional water molecules (AW) replaced by the piperidine ring and amide moieties when AVI is bound to Ser70, presumably creating a
conserved hydrogen bonding network in apo CTX-M-151.
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water during catalysis (9). These observations would support the role of Lys73 in the
proton relay pathway in b-lactam catalysis (29) and Glu166 as the general base in
deacylation (30, 31).
Comparative interaction of AVI with CTX-M-151 and other class A b-lactamases.
When the CTX-M-151/AVI complex structure was compared by superposition to other
class A b-lactamases, the RMSD values (in Å) for the C-a atoms between the main
chain of CTX-M-151 and other class A b-lactamases were 0.57 (CTX-M-15), 1.45 (SHV-1),
1.06 (KPC-2), 1.03 (L2), 1.06 (VCC-1), and 1.70 (PER-2). Also, the position and spatial
arrangement of AVI within the active site was conserved overall in all compared struc-
tures (Fig. 6a).
Although the degree of sequence similarity between CTX-M-151 and CTX-M-15 (or
other members within the family) was much lower (70%) than those between each of
the other CTX-M enzymes (.90%), a high conservation in the position of the catalyti-
cally relevant residues, accompanied by a tight conformational stability of the active
site, was noted. The only difference in the interaction between AVI and both enzymes
was the absence of a hydrogen bond between the sulfate moiety of AVI and Ser237 in
CTX-M-15 (separated by 3.39Å), and the presence of a direct hydrogen bond between
the carbonyl oxygen of the AVI carboxamide group and Asn104-Nd2 (Fig. 6b).
The mechanisms of AVI inhibition. Debate is still present regarding the mecha-
nism by which class A b-lactamases are inhibited by AVI. The consensus is that the cat-
alytic Ser70 residue is primed for the nucleophilic attack on the electrophilic C-7 car-
bonyl carbon atom of AVI creating a high-energy tetrahedral intermediate that results
in a carbamoyl enzyme intermediate.
We observed a possible protonation of Glu166 upon AVI binding, associated with a
shift in the position of Lys73 away from Glu166 and toward Ser130 (Fig. 5). This finding
agrees with previous observations in CTX-M-15/AVI (9) and the proposed mechanism
involving a proton shuttle from Lys73 to Ser130 in CTX-M b-lactamases (32). Moreover,
noting that Glu166 is deprotonated in the apo CTX-M-151 structure, and therefore
charged, converts this residue as the most probable general base in the priming of
Ser70 during the acylation step of AVI inhibition.
Conclusions. Using genetic, microbiological, biochemical, and structural tools, we
characterized CTX-M-151, a novel enzyme with the lowest degree of similarity within
the CTX-M family. Both the low relative percent identity compared to the rest of the
CTX-M members and its phylogenetic divergence from the five compact clusters within
the family prompted us to suggest that this variant may represent a new subgroup
within the family. It is also possible that this enzyme might represent a new group of
b-lactamases that are closely related to the CTX-Ms. At this point in time, further studies
are required to understand the place of this b-lactamase in the class A group of
enzymes. Additionally, insights into the structure of CTX-M-151 in complex with AVI
FIG 5 Differences in the orientation of Lys73 in the apo (left) and CTX-M-151/AVI complex (right) structures (see the
text for details). The 2mF0-DFc map (contoured at 1.5 s ) is shown in blue, and the mF0-DFc map (contoured at 3 s ) is
shown in red.
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revealed similar interactions of the inhibitor with residues in the active site of this singu-
lar ESBL, which support the efficacy of AVI toward a wide range of serine b-lactamases.
To our knowledge, this is the first ESBL found chromosomally encoded in S.
Choleraesuis. It is noteworthy that most of the chromosomally encoded ESBLs found in
Enterobacterales species show similar catalytic features, with hydrolytic preference to-
ward CTX/CRO compared to CAZ, i.e., CTX-M (Kluyvera spp.) (17, 33–35), FONA (Serratia
fonticola) (36), OXY (Klebsiella oxytoca) (37), RAHN (Rahnella aquatilis) (38), SFO
(Enterobacter cloacae) (39), and SMO (Ewingella sp.) (40). It is interesting to observe that
different enterobacterial species offer a portfolio of b-lactamases having equivalent
hydrolytic profiles. Whether the low efficiency in hydrolyzing CAZ compared to other
oxyimino-cephalosporins is a mere coincidence or is connected to other structural
properties of these enzymes (e.g., lower stability) remains to be further explored.
FIG 6 (a) Overlay positioning of AVI in the active site of different class A b-lactamases (stereo view). CTX-M-
151 (light orange/magenta), CTX-M-15 (yellow), KPC-2 (pink), SHV-1 (green), PER-2 (blue), L2 (orange). (b) Stereo
view showing the differences in the interaction of AVI in the active site of CTX-M-151 (light orange/magenta)
and CTX-M-15 (yellow/green). Common hydrogen bonds are shown as black dashed lines, whereas differential
interactions are shown in green. Red lines denote interactions that are missing due to a long distance between
the atoms involved (see the text for details).
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Experiments are under way to attempt to understand this important phenomenon, as
well as the place of this novel variant among other resistance determinants.
MATERIALS ANDMETHODS
Bacterial strains and plasmids. The blaCTX-M-151 gene was recovered from a S. Choleraesuis
TUM12370 strain isolated from a piglet’s feces in Tokyo, Japan, in 2014. E. coli ATCC 25922 was used for
quality control in antimicrobial susceptibility assays. E. coli DH5a (Invitrogen, USA) and E. coli BL21(DE3)
(Novagen, USA) were hosts for transformation experiments. Plasmid vectors pGEM-T easy vector
(Promega, USA) and kanamycin-resistant pET28a(1) (Novagen, Germany) were employed for routine
cloning experiments and for b-lactamase purification, respectively.
Chemical compounds. Avibactam (AVI) was acquired through an investigator-initiated trial with
Allergan. Ampicillin (AMP), aztreonam (ATM), cefepime (FEP), ceftazidime (CAZ), ceftriaxone (CRO), cefox-
itin (FOX), cephalothin (CEF), imipenem (IPM), and piperacillin (PIP) were obtained from Klonal
(Argentina). Nitrocefin (NCF) was purchased from Becton, Dickinson and from Oxoid.
Antimicrobial susceptibility testing. MICs were obtained by the broth microdilution method
according to the CLSI guidelines (41). AVI was used at a fixed concentration (4mg/ml) when combined
with CAZ. For recombinant E. coli BL21 clones expressing CTX-M-151, Mueller-Hinton broth was supple-
mented with 1 mM IPTG, and MIC was determined as above upon incubation at 37°C for 16 to 20 h.
Recombinant DNA methods. The blaCTX-M-151 gene was amplified by PCR from a recombinant E. coli
clone harboring the pET9a/blaCTX-M-151 plasmid (provided by Y. Ishii), using Phusion high-fidelity DNA
polymerase (Thermo Scientific, USA). Two PCR products were obtained using primers 151-Nco-F1-i.e.,
(59-CCATGGTCAATAAACGGCTGAGTATTGCTC-39) and 151-BamH-R1 (59-GGATCCTCAGCCTTTAGGCAATAC
ATAATGG-39) for the complete coding sequence (CDS) of blaCTX-M-151 and 151-Nde-F2-ht (59-CATATGG
CCCYCGAGAGCCAGAAG-39) and 151-BamH-R1 for the sequence encoding the mature CTX-M-151. The
PCR products were first cloned in a pTZ57R/T vector, and the insert was sequenced for verification of the
identity of the blaCTX-M-151 gene and generated restriction sites, as well as the absence of aberrant nucleotides.
Resulting recombinant pTZ57R/T plasmids were then digested, and the released inserts cloned in a pET28a
(1) vector. Ligation mixtures were used to first transform E. coli DH5a competent cells, and selected
recombinant clones were sequenced to confirm the identity of the blaCTX-M-151 gene. Then, those clones har-
boring the resulting pET plasmids were used for a second transformation step in E. coli BL21(DE3) competent
cells. E. coli carrying the full-length blaCTX-M-151 gene was used to determine the MICs, whereas E. coli express-
ing the mature form of CTX-M-151 was used for protein expression and purification.
DNA sequencing and bioinformatics. DNA sequences were determined at Macrogen, Inc. (South
Korea). Nucleotide and amino acid sequence analyses were conducted using NCBI (http://www.ncbi.nlm
.nih.gov/) and ExPASy (http://www.expasy.org/) analysis tools. Sequence and structural alignments were
also performed using T-Coffee Expresso (42) and ESPript/ENDscript (43). For the phylogenetic tree, 222
blaCTX-M nonredundant nucleotide sequences were downloaded from the GenBank database (http://
www.ncbi.nlm.nih.gov) in June 2020. The corresponding nucleotide sequences were aligned using
ClustalW, and the alignment was manually revised and modified where necessary. The maximum likeli-
hood phylogenetic tree of the revised alignment was obtained using the PhYML web server.
Evolutionary model selection was conducted using the Smart Model Selection (SMS) tool integrated into
the PhYML web server, and the Bayesian information criterion (BIC) was chosen as the selection criterion
(44, 45). The robustness of the relevant nodes was estimated with 1,000 bootstrap replicates.
Expression and purification of CTX-M-151. An overnight culture of recombinant E. coli BL21 produc-
ing CTX-M-151 was diluted (1/20) in 500ml lysogeny broth (LB) containing 30mg/ml kanamycin and grown
at 37°C until ca. 0.9 optical density (OD) units (l = 600nm). To induce b-lactamase expression, 1mM IPTG
was added. After 20 h of further incubation at 28°C, crude extracts were obtained through ultrasonic disrup-
tion, and after clarification by centrifugation at 10,000 g for 20min (4°C; Sorvall GS3 rotor), clear superna-
tants containing CTX-M-151 were dialyzed overnight against 2.5 liters of buffer A (50mM Tris and 200mM
NaCl [pH 8.0]). Clear supernatants were filtered by 0.45-mm-pore-size membranes and loaded onto a 5-ml
HisTrap high-performance (HP) column (GE Healthcare Life Sciences, USA), connected to an Äkta purifier
(GE Healthcare Life Sciences, USA) and preequilibrated with buffer A. The column was extensively washed
to remove unbound proteins, and b-lactamases were eluted with a linear gradient (0 to 100%; 2ml/min
flow rate) of buffer B (50mM Tris, 200mM NaCl, and 500mM imidazole [pH 8.0]). Eluted fractions were
screened in situ for b-lactamase activity during purification by NCF hydrolysis and confirmed by SDS-PAGE
in 12% polyacrylamide gels. Thrombin digestion (GE Healthcare Life Sciences) was performed overnight at
16°C to remove the histidine tag, according to the manufacturer’s indications, and the tag was further
removed by affinity chromatography in 1-ml HisTrap HP columns. Eluted proteins were conserved at –70°C
until use. Protein concentration and purity were determined by UV absorbance at 280nm (according to the
Lambert-Beer law and molar extinction coefficient) and by Coomassie blue staining on 15% SDS-PAGE gels,
respectively.
Kinetics. Steady-state kinetic parameters were determined using a T80 UV-visible spectrophotome-
ter (PG Instruments, Ltd., UK). Each reaction was performed in triplicate in 25 mM phosphate buffer (pH
7.0) at 22°C. The steady-state kinetic parameters Km and maximum rate of metabolism (Vmax) were
obtained as described previously (27, 46) with nonlinear least-squares fitting of the data (Henri
Michaelis-Menten equation) using Prism 5.03 for Windows (GraphPad Software, San Diego, CA) accord-
ing to Equation 1, as follows:
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v ¼ Vmax  S½ 
Km1 S½  (1)
For high Km values, the kcat values were derived by evaluation of the complete hydrolysis time
courses as described by De Meester et al. (47). For poor substrates behaving as competitive inhibitors,
apparent Km values were determined as Ki by monitoring the residual activity of the enzyme in the pres-
ence of various concentrations of the drug and 100 mM nitrocefin as the reporter substrate in competi-
tion experiments, according to the following expression (Equation 2):
v ¼ VðSÞ= Sð Þ1Km 11 IKi
  
(2)
in which Km and S correspond to the reporter substrate and I is the variable concentration for the
competitive substrate.
For irreversible inhibitors (clavulanic acid), the rate constant of inactivation (kinact) was measured
directly by time-dependent inactivation of CTX-M-151 in the presence of the inhibitor, using a fixed con-
centration of enzyme and 100mM NCF as a reporter and increasing concentrations of the inhibitor (con-
centration range, 0.055 to 1.1mM). The observed rate constant for inactivation (kobs) was determined by
nonlinear least-squares fitting of the data using OriginPro 8.0 (Northampton, MA), using Equation 3, as
described elsewhere (26, 48).
The interaction of CTX-M-151 with AVI was assumed to follow the models of other b-lactamases
except that of KPC-2 (1), proposed by Ehmann (2), on the basis of the scheme shown in Fig. 1b, where Ki
(k21/k1) is the dissociation constant of the EI complex (also referred to as K in some references) (49, 50).
The inhibition constants Ki and k2/K were determined as reported previously for AVI in competitive
assays using 110 mM NCF (as a reporter substrate) and increasing AVI concentrations (range, 0.024 to
1.6mM) (27). Progress curves were subsequently fitted to Equation 3 to obtain kobs values.
A ¼ A01 vf  t1 v02 vfð Þ  12 e2kobstð Þ=kobs (3)
Finally, kobs values were plotted against [AVI], and the k2/K value was obtained by correcting the
value for the slope of the line for the concentration and affinity of NCF (Equation 4).
k2=Kcorrected ¼ k2=Kobs  ½ð½S=Km nitrocefinÞ1 1 (4)
The koff value was determined by incubating the CTX-M-151 with an AVI concentration that resulted
in complete inhibition, as follows: 1mM enzyme was preincubated with 120mM AVI, samples were seri-
ally diluted (1:2,000), and hydrolysis of 100mM NCF was measured. Progress curves were fitted to a sin-
gle exponential decay equation as previously described (1, 27).
The following extinction coefficients and wavelengths were used (51): ampicillin (D« 235 =
2820 M21 · cm21), cephalothin (D« 273 = 26,300 M
21 · cm21), CAZ (D« 260 = 29,000 M
21 · cm21), CRO
(D« 260 = 29,400 M
21 · cm21), cefepime (D« 260 = 210,000 M
21 · cm21), aztreonam (D« 318 = 2750 M
21 ·
cm21), and nitrocefin (D« 482 =115,000 M
21 · cm21).
Crystallization of apo and AVI-bound CTX-M-151. Crystals of apo CTX-M-151 were grown by the
hanging drop vapor diffusion method (20°C) with drops containing 2 ml of enzyme solution (20mg/ml)
and 2 ml of crystallization solution consisting of 21% (wt/vol) polyethylene glycol (PEG) 8,000 and 0.1 M
HEPES (pH 7.8). The AVI adduct was obtained by soaking apo CTX-M-151 crystals in crystallization solu-
tion supplemented with 100mM AVI for 24 h. All samples were cryoprotected in mother liquor with 15%
(wt/vol) PEG 400 added and then flash-cooled in liquid nitrogen in Hampton Research loops (Aliso Viejo,
USA).
Data collection, phasing, and model building and refinement. Native X-ray diffraction data were
collected at 100 K at the Proxima 2A beamline at the Soleil Synchrotron (Saint Aubin, France), using a
Dectris Eiger X 9M detector. Integration and scaling were carried out using XDS software (52). Structure
resolution was achieved by molecular replacement through Phaser (53), using the CTX-M-14 structure
(Protein Data Bank [PDB] code 4UA6) as a starting model (54). Refinement and model building were per-
formed with Phenix 1.12-2829 (55) and Coot 0.8.6.1 (Turtle Bay) (56), respectively. Models were visualized
with PyMOL 1.7.0.3 (57).
Accession number(s). The coordinates and structure factor amplitudes of apo CTX-M-151 and the
CTX-M-151/AVI complex were deposited in the Protein Data Bank (PDB) under accession codes 6BN3
and 6BPF, respectively.
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